A phase II study to determine relapse-free interval after withdrawal of imatinib therapy in adult patients with chronic phase chronic myeloid leukaemia in stable complete molecular remission (CML08)

Distribution of genomic breakpoints in chronic myeloid leukemia: analysis of 308 patients

doi : http://doi.org/10.1038/leu.2013.116

Reverse Transcription with Random Pentadecamer Primers Improves the Detection Limit of a Quantitative PCR Assay for BCR-ABL Transcripts in Chronic Myeloid Leukemia: Implications for Defining Sensitivity in Minimal Residual Disease

doi : http://doi.org/10.1373/clinchem.2008.105916

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR

doi : http://doi.org/10.1038/leu.2010.185

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

doi : http://doi.org/10.1182/blood-2013-02-483750

BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management

doi : http://doi.org/10.1182/blood-2011-11-393041

Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML

doi : http://doi.org/10.1182/blood-2012-10-462291

Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells

doi : http://doi.org/10.1038/s41375-018-0264-0

Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission

doi : http://doi.org/10.1182/blood.2019000120

Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission

doi : http://doi.org/10.1038/s41375-019-0647-x

Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells

doi : http://doi.org/10.1111/bjh.16718

Australasian Leukaemia And Lymphoma Group (ALLG)

ROR : https://ror.org/05t72y326

Australasian Leukaemia and Lymphoma Group (ALLG)

ROR : https://ror.org/05t72y326